Business

Cases of rare blood clots identified after AstraZeneca Covid-19 jabs

Share
Source BBC

The British-Swedish company has been plagued by several issues, including a row over vaccine deliveries with the European Union as the continent battles with rising infections and reports of blood clotting after people received the shot.

On Thursday, Britain identified 30 cases of rare blood clot events following use of the vaccine, and several countries, including Canada, France, Germany and Spain, limited its use after similar reports.

As of March 24, there were 22 cases of cerebral venous sinus thrombosis and another eight cases of thrombosis with low platelets.

"This is a very safe vaccine, it's saving a lot of lives and we've seen how these types of stories have damaged vaccination campaigns in other parts of the world".

CVST clots stop blood draining from the brain properly. And even if they are, British and European regulators have said they were so rare that the vaccine should continue to be used.

However, Australia's Therapeutic Goods Administration and the European Medicines Agency continue to back the rollout of the AstraZeneca vaccine. In late March, CSL Ltd began domestic production of 50 million doses.

"The benefits of the vaccines against Covid-19 continue to outweigh any risks", the Medicines and Healthcare products Regulatory Agency (MHRA) said, urging the public to keep taking the vaccine.

The Netherlands has temporarily halted the use of the AstraZeneca Covid-19 vaccine for people under the age of 60, the Ministry of Health, Welfare and Sport.

However, Ireland's medicines watchdog has said that none of the reports notified described the type of disorder associated with concerns about the AstraZeneca vaccine.

The decision to suspend use of the vaccine is a further blow to the Dutch vaccination campaign which is running behind schedule.

There were no reports of people who had the Pfizer/BioNTech suffering from blood clots.

He said the potential for blood clots after receiving the vaccine would "continue to be monitored, but that doesn't mean it's something of concern that would mean people should not be coming forward to get the vaccine".

She added that all studies indicated the vaccine was safe and effective, while the fact different nations were reviewing their position was a sign that the "system was working".

Last week, Britain announced a third coronavirus vaccine from United States firm Moderna (MRNA) will be rolled out in the United Kingdom from April and will join the AstraZeneca and Pfizer (PFE)/ BioNtech (BNTX) jabs already being offered on the NHS.

Many have resumed the vaccine's use only for older people, aged 55 and above, because the blood clots are believed to affect younger people.

In November, the United Kingdom became the first Western country to approve a coronavirus vaccine.

Share